LQDA Options (LQDA20260306P28.5) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About LQDA20260306P28.5

Underlying

Liquidia Corporation

Industry

Pharmaceutical

Introduction

Liquidia Corporation was incorporated in Delaware on June 17, 2020. The company is a biopharmaceutical company focused on the development, manufacturing and commercialization of products that address unmet patient needs, with a current focus on the treatment of pulmonary hypertension. The company operates as a single entity through two wholly-owned subsidiaries, Liquidia Technologies and Liquidia PAH. The company conducts research, development and manufacture of new products by applying its expertise in cardiopulmonary disease and proprietary PRINT technology, a particle engineering platform capable of accurately producing uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through product development and research with third parties, the company has experience in applying PRINT to a variety of drug delivery routes and drug payloads, including inhalation therapies, vaccines, biological agents, nucleic acids and ophthalmic implants.